- Home
- BGI vs SNSE Comparison
BGI vs SNSE Comparison
Compare BGI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGI | SNSE |
|---|---|---|
| Founded | 1879 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.2M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BGI | SNSE |
|---|---|---|
| Price | $0.63 | $13.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | ★ 60.4K | 37.9K |
| Earning Date | 12-05-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $5.86 |
| 52 Week High | $1.57 | $36.76 |
Technical Indicators
Market Signals| Indicator | BGI | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 40.54 |
| Support Level | $0.63 | $8.27 |
| Resistance Level | $0.70 | $18.35 |
| Average True Range (ATR) | 0.06 | 2.55 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 83.14 | 32.46 |
Price Performance
Historical ComparisonAbout BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).